Oshrat Levi
@Sphera Funds Management Ltd.
Latest period2024 - Q3ReportedManaged Assets$628.383MTotal holdings109
Assets growth rate-14.3%Assets growth rate (2-Q avg)-5.64%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Sphera Funds Management Ltd.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 109 positions.
Assets under management
The assets under management (AUM) of Sphera Funds Management Ltd. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 628.383M in assets, with a quarterly growth rate of -14.3% and a 2-quarter average growth rate of -5.64%. The portfolio is managed by Oshrat Levi, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
MSFTMicrosoft Corp
| 2.29% | $14.384M 33,427 shares@ $430.3 avg price | Increased 1.52% |
CLDXCelldex Therapeutics Inc New
| 2.27% | $14.245M 419,103 shares@ $34.0 avg price | Increased 35.52% |
AAPLApple Inc
| 2.26% | $14.177M 60,847 shares@ $233.0 avg price | Decreased -1.06% |
PRAXPraxis Precision Medicines I
| 2.24% | $14.057M 244,307 shares@ $57.55 avg price | Decreased -31.83% |
KURAKura Oncology Inc
| 1.9% | $11.921M 610,087 shares@ $19.55 avg price | Decreased -0.12% |
LLYEli Lilly & Co
| 1.86% | $11.686M 13,190 shares@ $885.95 avg price | |
JNJJohnson & Johnson
| 1.81% | $11.317M 69,831 shares@ $162.07 avg price | |
RAREUltragenyx Pharmaceutical In
| 1.73% | $10.852M 195,349 shares@ $55.56 avg price | Decreased -33.51% |
NVMINova Ltd
| 1.73% | $10.825M 51,960 shares@ $208.34 avg price | New Position |
NVONovo-nordisk A S
| 1.48% | $9.297M 78,080 shares@ $119.08 avg price |